Pinc PeptideThe girly peptide research blog

BPC-157 · Dose evidence · updated 8 October 2026

BPC-157 dosage: what studies actually used

The short answer

Published human studies of BPC-157 used enemas (0.25 to 2 mg/kg, or 80 mg once a day for 2 weeks), 2 to 4 mg injected into the knee, 10 mg injected into the bladder wall and IV infusions of 10 and 20 mg1234. None of them gave it under the skin, by mouth or in the nose1; an 8-week study of gummies (500 µg per serving) has posted no results5. No dose has been shown to work or to be safe in people, and FDA calls the doses studied so far ‘likely exploratory in nature’1.

Not dosing advice. This page reports doses that studies and approved labels used, with their sources. It does not recommend a dose, and we do not give mixing, injection or unit-conversion instructions. Gray-market vials often do not contain what their label says. How we report doses.

Every dose studied in people

StudyWhoPeopleDose and routeWhat happened
Ruenzi 2005, randomized placebo-controlled Phase II trial (meeting abstract) Adults with mild to moderate ulcerative colitis 53 80 mg once a day
Rectal enema · 2 weeks		 46 of 53 finished, and the disease score fell 3.2 points on BPC-157 and 1.6 on placebo, a difference that was not statistically significant1. FDA called the data inadequate to support efficacy or safety1.
Veljaca 2002 and 2003, placebo-controlled Phase 1 study (meeting abstracts) Healthy men; 24 given BPC-157 and 8 placebo 32 0.25, 0.5, 1 or 2 mg/kg: one dose, then once a day after a 1-week break
Rectal enema · One dose, then 7 days		 No significant adverse events were attributed to the drug; headache and flatulence were most common, with no obvious difference from placebo, and most blood samples held too little drug to measure1.
Lee 2021, chart review with no control group Knee-pain patients at one Florida clinic; 4 also received ‘TB4’ (thymosin beta-4, per FDA) 17 2 to 4 mg, given once or twice
Injection into the knee joint · 1 or 2 injections; phone follow-up mostly 6 months to 1 year later		 16 of the 17 were reached by phone, and 14 of those 16 said their pain was significantly relieved; the authors noted no adverse events12.
Lee 2024, single-arm pilot study Women with interstitial cystitis (bladder pain syndrome) not helped by pentosan polysulfate 12 1 mg at each of 10 sites, 10 mg in total
Injection into the bladder wall through a scope (cystoscopy) · One procedure		 10 of 12 rated their improvement at 100% (complete relief) and 2 at 80%; no adverse events were reported, and there was no control group3.
Lee 2025, safety pilot with no control group Adults who had used IV BPC-157 before 2 10 mg on day 1, then 20 mg on day 2
IV infusion over 1 hour · 2 days		 No side effects were reported, and blood markers of heart, liver, kidney and thyroid function and blood sugar showed no measurable change4.
Parlay Wellness 2025 (NCT07752381), single-group industry study (registry record only) Physically active adults 40 Two gummies a day; 500 µg of BPC-157 per serving
By mouth (gummies, listed as a dietary supplement) · 8 weeks		 Finished in November 2025 and was registered only afterwards, in August 2026; no results have been posted5.

Studies, animals and users: kept apart

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

None of the five clinical studies FDA found tested injection under the skin, oral use or nasal use1. Doses in published studies: a rectal enema of 0.25, 0.5, 1 or 2 mg/kg, once and then daily for 7 days, in healthy volunteers1; an 80 mg enema daily for 2 weeks in ulcerative colitis, with no significant benefit1; 2 to 4 mg injected into the knee, 1 or 2 times12; 10 mg injected into the bladder wall in one procedure3; and 10 mg by IV infusion on day 1, then 20 mg on day 24. A 2015 oral study planned single doses of 1, 3 or 6 mg, then 3 mg every 8 hours for 2 weeks; it has posted no results, and FDA found no published study from it17. An industry study in which 40 people took two BPC-157 gummies a day for 8 weeks (500 µg per serving) finished in November 2025 but has posted no results5.

In animal studies

Early animal studies mostly used very low doses, in the microgram and nanogram per kg range8. Rat healing studies typically gave 10 µg/kg or 10 ng/kg once daily, injected into the abdominal cavity (intraperitoneal) or added to drinking water19. The 2003 Achilles tendon study also tested 10 pg/kg9, and a 2026 Achilles study used 10 µg/kg per day for 4 weeks10. FDA notes that dose-response relationships for its effects on gut and liver injuries have not been established1. Toxicology studies used far larger intramuscular doses: the highest single doses with no observed adverse effects were 20 mg/kg in rats and 10 mg/kg in dogs, and 28-day studies went up to 4 mg/kg per day in rats and 2 mg/kg per day in dogs111. These are animal research doses, not human doses.

What users report Anecdotal · not validated · not a recommendation

One community reference page lists 500 µg (micrograms) per dose, once or twice a day6.

Half-life and how it is taken

Half-life
About 15 minutes in rats and 5 minutes in dogs after an IV dose; unknown in humans12Animal data only: after single IV doses, 15.2 minutes in rats (20 µg/kg) and 5.3 minutes in dogs (6 µg/kg)1. The study authors report a half-life under 30 minutes and rapid breakdown into small peptide fragments12. FDA found no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use; in the enema studies, BPC-157 was not detected in most plasma samples1.
Routes
  • Subcutaneous injection (not used in any clinical study FDA found)
  • Oral capsules, tablets, gummies and sprays (sold as supplements and compounded products; a 2015 oral study and a 2025 gummy study have posted no results)
  • Nasal spray (no human data found)
  • Intramuscular injection (animal studies only)
  • Rectal enema (human studies reported 2002 to 2005)
  • Knee (intra-articular) injection (retrospective case series)
  • Injection into the bladder wall (single-arm pilot)
  • Intravenous infusion (2-person pilot)
  • Transdermal cream (proposed in a withdrawn compounding nomination; no human data found)

Why there is no established dose

The only controlled trial in patients that FDA found showed no significant benefit, and FDA says the human studies ‘evaluated doses that were likely exploratory in nature’1. Even in animals, FDA says, dose-response relationships, meaning links between the size of a dose and its effect, have not been established for BPC-157’s effects on gut and liver injuries1. The five published studies FDA found gave BPC-157 to fewer than 100 people, for 2 weeks or less; an 8-week study of gummies has posted no results15.

FDA found no published study that gave BPC-157 to people under the skin, by mouth or in the nose, and no human data on how much reaches the blood by those routes1. The 500 µg per dose listed on a community reference page was not used in any of the five human studies FDA found; a registered study of gummies with 500 µg per serving has posted no results156.

Vials may not hold what the label says: 92 of Finnrick’s latest 200 BPC-157 tests, from May to September 2026, failed its purity-focused standard (at least 99.5% pure and within 35% of the labeled amount), and a vial bought at a Brooklyn corner shop and tested for WIRED held no BPC-157131415.

Registered trials that have not reported

Trial registries list a few more BPC-157 studies, but none has posted results5716.

  • A 2015 study of oral ‘Bepecin’ tablets in healthy volunteers in Mexico has posted no results, and FDA found no published study from it17.
  • An industry study of BPC-157 gummies at 500 µg per serving finished in November 2025 but has posted no results5.
  • A trial after rotator cuff surgery is not due to start until January 202716.

A 2026 hamstring ‘trial’ listing (NCT07437547) is not counted here, because another record from the same sponsor calls itself ‘fictional’1718.

Questions people ask

How much BPC-157 should I take?

No dose of BPC-157 is established for any use: FDA says the human studies ‘evaluated doses that were likely exploratory in nature’1. Published human studies used enemas, 2 to 4 mg injected into the knee, 10 mg injected into the bladder wall and IV infusions of 10 and 20 mg, and none tested injection under the skin1234. BPC-157 is not an approved drug, and US pharmacies may not compound it119.

Is it bad to take BPC-157 every day?

None of the five clinical studies FDA found gave BPC-157 to people every day for longer than 2 weeks, or by daily injections under the skin, so the effects of everyday use are unknown1. A registered study in which 40 people took BPC-157 gummies every day for 8 weeks has posted no results5. FDA says 28-day studies of daily doses in rats and dogs showed possible signs of altered blood clotting and raised liver-related blood markers, and it found no study of BPC-157’s cancer risk111. FDA says it ‘lacks sufficient information to know whether the drug would cause harm when administered to humans’20.

How long were people given BPC-157 in studies?

In published studies, no longer than 2 weeks: the longest course was an 80 mg enema once a day for 2 weeks in ulcerative colitis1. The other published studies gave one dose followed by 7 daily doses, one or two knee injections, one bladder procedure, or IV infusions on 2 days in a row1234. A registered industry study gave 40 people two BPC-157 gummies a day for 8 weeks; it finished in November 2025 but has posted no results5.

Go deeper

Sources

  1. 1FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
  2. 2Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Alternative Therapies in Health and Medicine, Jul 2021. pubmed.ncbi.nlm.nih.gov
  3. 3Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Alternative Therapies in Health and Medicine, Oct 2024. pubmed.ncbi.nlm.nih.gov
  4. 4Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Alternative Therapies in Health and Medicine, Sep 2025. pubmed.ncbi.nlm.nih.gov
  5. 5A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery (NCT07752381) ClinicalTrials.gov, 7 Aug 2026. clinicaltrials.gov
  6. 6BPC-157: How It Works, Mechanism & Evidence (2026) The Peptide Catalog, 18 Apr 2026. thepeptidecatalog.com
  7. 7PCO-02 - Safety and Pharmacokinetics Trial (NCT02637284) ClinicalTrials.gov, 22 Dec 2015. clinicaltrials.gov
  8. 8A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC Journal of Physiology, Paris, 1993. pubmed.ncbi.nlm.nih.gov
  9. 9Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Journal of Orthopaedic Research, Nov 2003. pubmed.ncbi.nlm.nih.gov
  10. 10Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint Diseases and Related Surgery, 23 Jul 2026. pubmed.ncbi.nlm.nih.gov
  11. 11Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds Regulatory Toxicology and Pharmacology, Jul 2020. pubmed.ncbi.nlm.nih.gov
  12. 12Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs Frontiers in Pharmacology, 2022. pubmed.ncbi.nlm.nih.gov
  13. 13BPC-157 Safety Testing Results & Vendor Ratings Finnrick, 29 Sep 2026. finnrick.com
  14. 14Those Viral Bodega Peptides Aren’t Actually Peptides WIRED, 15 Sep 2026. wired.com
  15. 15Methodology Finnrick, accessed 30 Sep 2026. finnrick.com
  16. 16Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250) ClinicalTrials.gov, 3 Sep 2026. clinicaltrials.gov
  17. 17BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547) ClinicalTrials.gov, 27 Feb 2026. clinicaltrials.gov
  18. 18TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (NCT07487363) ClinicalTrials.gov, 23 Mar 2026. clinicaltrials.gov
  19. 19Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  20. 20Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov

Not medical advice. Talk to a licensed clinician before using any drug. Report an error.